Lieping Chen
Discovered PD-L1 (B7-H1) and showed tumours use it to escape immunity, the biology behind every anti-PD-1 drug.
Overview
Lieping Chen (Yale) identified B7-H1, later named PD-L1, in 1999, showed in 2002 that tumours express it to kill or disable T cells and that blocking it restores anti-tumour immunity, and initiated the first anti-PD-1/PD-L1 clinical trials with Johns Hopkins colleagues. He received the Warren Alpert Prize with Honjo, Freeman and Sharpe and continues to discover normalisation-cancer-immunotherapy targets such as Siglec-15.
| Title | Journal | Year |
|---|---|---|
| B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Nature Medicine | 1999 |
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Nature Medicine | 2002 |
This study is why PD-1 inhibitors were developed across cancers rather than in melanoma alone: unexpected activity in lung cancer, historically thought immune-resistant, changed drug development priorities industry-wide. It also introduced PD-L1 immunohistochemistry as a candidate biomarker and pneumonitis as a signature toxicity. Within five years PD-1 blockade was approved in more than ten cancers.
Tumours hide from T cells by displaying PD-L1; blocking that interaction lets the immune system attack. This is the mechanism of pembrolizumab, nivolumab, atezolizumab and their relatives, which now treat more than 20 cancer types.
Pages like this
not linked directly; found by shared links- PersonGordon J. Freeman
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, PD-L1, PD-1, Immune checkpoint inhibitors and the tags immunotherapy, discovery.
- PersonArjun V. Balar
Shares PD-L1, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonDrew M. Pardoll
Shares Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack, Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, PD-L1, PD-1.
- CompanyOnc.AI
Shares PD-L1, PD-1, Immune checkpoint inhibitors.
- PersonJoaquim Bellmunt
Shares PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonTimothy F. Cloughesy
Shares PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonPeter Schmid
Shares PD-L1, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonAnna K. Nowak
Shares PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.